94 related articles for article (PubMed ID: 32703126)
21. Cellular binding partners of the human papillomavirus E6 protein.
Tungteakkhun SS; Duerksen-Hughes PJ
Arch Virol; 2008; 153(3):397-408. PubMed ID: 18172569
[TBL] [Abstract][Full Text] [Related]
22. Differential localization of HPV16 E6 splice products with E6-associated protein.
Vaeteewoottacharn K; Chamutpong S; Ponglikitmongkol M; Angeletti PC
Virol J; 2005 Jun; 2():50. PubMed ID: 15960845
[TBL] [Abstract][Full Text] [Related]
23. Molecular Probing of the HPV-16 E6 Protein Alpha Helix Binding Groove with Small Molecule Inhibitors.
Rietz A; Petrov DP; Bartolowits M; DeSmet M; Davisson VJ; Androphy EJ
PLoS One; 2016; 11(2):e0149845. PubMed ID: 26915086
[TBL] [Abstract][Full Text] [Related]
24. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins.
Baleja JD; Cherry JJ; Liu Z; Gao H; Nicklaus MC; Voigt JH; Chen JJ; Androphy EJ
Antiviral Res; 2006 Oct; 72(1):49-59. PubMed ID: 16690141
[TBL] [Abstract][Full Text] [Related]
25. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
26. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein.
Beerheide W; Bernard HU; Tan YJ; Ganesan A; Rice WG; Ting AE
J Natl Cancer Inst; 1999 Jul; 91(14):1211-20. PubMed ID: 10413422
[TBL] [Abstract][Full Text] [Related]
27. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent.
Tomaić V; Pim D; Banks L
Virology; 2009 Oct; 393(1):7-10. PubMed ID: 19700180
[TBL] [Abstract][Full Text] [Related]
28. Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
Stutz C; Reinz E; Honegger A; Bulkescher J; Schweizer J; Zanier K; Travé G; Lohrey C; Hoppe-Seyler K; Hoppe-Seyler F
PLoS One; 2015; 10(7):e0132339. PubMed ID: 26151636
[TBL] [Abstract][Full Text] [Related]
29. Genetic variations in human papillomavirus and cervical cancer outcomes.
Rader JS; Tsaih SW; Fullin D; Murray MW; Iden M; Zimmermann MT; Flister MJ
Int J Cancer; 2019 May; 144(9):2206-2214. PubMed ID: 30515767
[TBL] [Abstract][Full Text] [Related]
30. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
Rezhake R; Hu SY; Zhao S; Xu XQ; Zhao XL; Zhang L; Wang Y; Zhang X; Pan QJ; Qiao YL; Zhao FH
Int J Cancer; 2019 Jan; 144(1):34-42. PubMed ID: 29943809
[TBL] [Abstract][Full Text] [Related]
31. Virtual Screening for Potential Inhibitors of High-Risk Human Papillomavirus 16 E6 Protein.
Kumar S; Jena L; Mohod K; Daf S; Varma AK
Interdiscip Sci; 2015 Jun; 7(2):136-42. PubMed ID: 26199214
[TBL] [Abstract][Full Text] [Related]
32. High risk HPV E6 oncoproteins impair the subcellular distribution of the four and a half LIM-only protein 2 (FHL2).
Manzo-Merino J; Massimi P; Banks L; Lizano M
Virology; 2015 Feb; 476():100-105. PubMed ID: 25540819
[TBL] [Abstract][Full Text] [Related]
33. Role of Cdk1 in the p53-independent abrogation of the postmitotic checkpoint by human papillomavirus E6.
Zhang W; Liu Y; Zhao N; Chen H; Qiao L; Zhao W; Chen JJ
J Virol; 2015 Mar; 89(5):2553-62. PubMed ID: 25520504
[TBL] [Abstract][Full Text] [Related]
34. Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53.
Ansari T; Brimer N; Vande Pol SB
J Virol; 2012 Oct; 86(20):11386-91. PubMed ID: 22896608
[TBL] [Abstract][Full Text] [Related]
35. Analysis of specificity determinants in the interactions of different HPV E6 proteins with their PDZ domain-containing substrates.
Thomas M; Dasgupta J; Zhang Y; Chen X; Banks L
Virology; 2008 Jul; 376(2):371-8. PubMed ID: 18452965
[TBL] [Abstract][Full Text] [Related]
36. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
Poirson J; Biquand E; Straub ML; Cassonnet P; Nominé Y; Jones L; van der Werf S; Travé G; Zanier K; Jacob Y; Demeret C; Masson M
FEBS J; 2017 Oct; 284(19):3171-3201. PubMed ID: 28786561
[TBL] [Abstract][Full Text] [Related]
37. Elucidating Molecular Interactions of Ten Natural Compounds Targeting E6 HPV High Risk Oncoproteins Using Microsecond Molecular Dynamics Simulations.
Meza-Menchaca T; Lizano-Soberón M; Trigos A; Zepeda RC; Medina ME; Galindo-Murillo R
Med Chem; 2021; 17(6):587-600. PubMed ID: 31995016
[TBL] [Abstract][Full Text] [Related]
38. Competitive binding to a charged leucine motif represses transformation by a papillomavirus E6 oncoprotein.
Bohl J; Das K; Dasgupta B; Vande Pol SB
Virology; 2000 May; 271(1):163-70. PubMed ID: 10814581
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis.
Chen PM; Cheng YW; Wang YC; Wu TC; Chen CY; Lee H
Neoplasia; 2014 Nov; 16(11):961-71. PubMed ID: 25425970
[TBL] [Abstract][Full Text] [Related]
40. E6 Protein Expressed by High-Risk HPV Activates Super-Enhancers of the
Chen X; Loo JX; Shi X; Xiong W; Guo Y; Ke H; Yang M; Jiang Y; Xia S; Zhao M; Zhong S; He C; Fu L; Li F
Cancer Res; 2018 Mar; 78(6):1418-1430. PubMed ID: 29339538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
